TROVAFLOXACIN HYDROCHLORIDE

US Previously Marketed

First approved in 1997

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H15F3N4O3.ClH
Molecular Weight	452.814
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of TROVAFLOXACIN HYDROCHLORIDE

Structure Search

SMILES

Cl.[H][C@@]12CN(C[C@]1([H])[C@H]2N)C3=NC4=C(C=C3F)C(=O)C(=CN4C5=CC=C(F)C=C5F)C(O)=O

InChI

InChIKey=VOYNIHWZMLJQHF-AHZSKCOESA-N

InChI=1S/C20H15F3N4O3.ClH/c21-8-1-2-15(13(22)3-8)27-7-12(20(29)30)17(28)9-4-14(23)19(25-18(9)27)26-5-10-11(6-26)16(10)24;/h1-4,7,10-11,16H,5-6,24H2,(H,29,30);1H/t10-,11+,16+;

HIDE SMILES / InChI

Molecular Formula	C20H15F3N4O3
Molecular Weight	416.3533
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.drugbank.ca/drugs/DB00685https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da9b26bb-d2d7-4113-a0f9-c6c2280f4875#Clinical_Pharmacology
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/dosage/trovan.html

Alatrofloxacin is a fluoroquinolone antibiotic developed as a mesylate salt and was sold under brand name Trovan, but was withdrawn from the U.S. market in 2001. Trovan was indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. After intravenous administration, alatrofloxacin is rapidly converted to trovafloxacin, which is responsible for therapeutic effect. Plasma concentrations of alatrofloxacin are below quantifiable levels within 5 to 10 minutes of completion of a 1 hour infusion.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Plasmodium falciparum 74 Target ID: CHEMBL364 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12878530	Inhibitor 8297
Streptococcus pneumoniae 25 Target ID: CHEMBL347 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11892894	Inhibitor 8297
Moraxella catarrhalis 10 Target ID: CHEMBL614429 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11892894	Inhibitor 8297
Staphylococcus aureus 67 Target ID: CHEMBL352 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20407243	Inhibitor 8297
Escherichia coli 82 Target ID: CHEMBL354 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11418510	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Nosocomial pneumonia 10 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a.pdf	Curative	Withdrawn	TROVAN PRESERVATIVE FREE Approved Use Trovan is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. NOTE: Trovan has not been studied in the treatment of osteomyelitis. Launch Date 1997
Pneumonia 90 Sources: https://www.drugs.com/pro/trovan.html	Curative	Approved 8429	TROVAN Approved Use Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. Launch Date 1997
Intra-abdominal infections 49 Sources: https://www.drugs.com/dosage/trovan.html	Curative	Approved 8429	TROVAN Approved Use Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. Launch Date 1997
Complicated skin and skin structure infections 11 Sources: https://www.drugs.com/dosage/trovan.html	Curative	Approved 8429	TROVAN Approved Use Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. Launch Date 1997
Pneumonia 90 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a.pdf	Curative	Withdrawn	TROVAN PRESERVATIVE FREE Approved Use Trovan is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. NOTE: Trovan has not been studied in the treatment of osteomyelitis. Launch Date 1997
Complicated intra-abdominal infections 20 Sources: https://www.drugs.com/pro/trovan.html#Indications_And_Usage	Curative	Withdrawn	TROVAN PRESERVATIVE FREE Approved Use Trovan is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. NOTE: Trovan has not been studied in the treatment of osteomyelitis. Launch Date 1997
Gynecologic infections 18 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a.pdf	Curative	Withdrawn	TROVAN PRESERVATIVE FREE Approved Use Trovan is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. NOTE: Trovan has not been studied in the treatment of osteomyelitis. Launch Date 1997
Skin infections 59 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a.pdf	Curative	Withdrawn	TROVAN PRESERVATIVE FREE Approved Use Trovan is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, or Staphylococcus aureus. As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae. Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. NOTE: Trovan has not been studied in the treatment of osteomyelitis. Launch Date 1997

C_max

Value	Dose	Analyte	Population
1.1 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
2.9 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
3.3 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
2.9 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9935250	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
11.8 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
26.2 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
34.6 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
9.4 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
32.2 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9935250	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
10.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
10.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
12.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
9.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
13.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9935250	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

F_unbound

Value	Dose	Analyte	Population
22% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
25.6% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
28.3% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
20.3% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8737145	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	TROVAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
1000 mg single, oral Highest studied dose Dose: 1000 mg Route: oral Route: single Dose: 1000 mg Sources: https://pubmed.ncbi.nlm.nih.gov/8522468/	healthy, 27 years n = 4 Health Status: healthy Age Group: 27 years Sex: M Population Size: 4 Sources: https://pubmed.ncbi.nlm.nih.gov/8522468/	Other AEs: Nausea, Vomiting... Other AEs: Nausea (4 patients) Vomiting (1 patient) Lightheadedness (4 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/8522468/
200 mg 1 times / day steady, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9758292/	unhealthy, adult n = 881 Health Status: unhealthy Condition: chronic bronchitis or pneumonia Age Group: adult Sex: M+F Population Size: 881 Sources: https://pubmed.ncbi.nlm.nih.gov/9758292/	Disc. AE: Gastrointestinal disorder NOS, CNS disorder (NOS)... AEs leading to discontinuation/dose reduction: Gastrointestinal disorder NOS (11 patient) CNS disorder (NOS) (4 patients) Dizziness (2 patients) Dermatitis (2 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/9758292/

AEs

AE	Significance	Dose	Population
Vomiting	1 patient	1000 mg single, oral Highest studied dose Dose: 1000 mg Route: oral Route: single Dose: 1000 mg Sources: https://pubmed.ncbi.nlm.nih.gov/8522468/	healthy, 27 years n = 4 Health Status: healthy Age Group: 27 years Sex: M Population Size: 4 Sources: https://pubmed.ncbi.nlm.nih.gov/8522468/
Lightheadedness	4 patients	1000 mg single, oral Highest studied dose Dose: 1000 mg Route: oral Route: single Dose: 1000 mg Sources: https://pubmed.ncbi.nlm.nih.gov/8522468/	healthy, 27 years n = 4 Health Status: healthy Age Group: 27 years Sex: M Population Size: 4 Sources: https://pubmed.ncbi.nlm.nih.gov/8522468/
Nausea	4 patients	1000 mg single, oral Highest studied dose Dose: 1000 mg Route: oral Route: single Dose: 1000 mg Sources: https://pubmed.ncbi.nlm.nih.gov/8522468/	healthy, 27 years n = 4 Health Status: healthy Age Group: 27 years Sex: M Population Size: 4 Sources: https://pubmed.ncbi.nlm.nih.gov/8522468/
Gastrointestinal disorder NOS	11 patient Disc. AE	200 mg 1 times / day steady, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9758292/	unhealthy, adult n = 881 Health Status: unhealthy Condition: chronic bronchitis or pneumonia Age Group: adult Sex: M+F Population Size: 881 Sources: https://pubmed.ncbi.nlm.nih.gov/9758292/
Dermatitis	2 patients Disc. AE	200 mg 1 times / day steady, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9758292/	unhealthy, adult n = 881 Health Status: unhealthy Condition: chronic bronchitis or pneumonia Age Group: adult Sex: M+F Population Size: 881 Sources: https://pubmed.ncbi.nlm.nih.gov/9758292/
Dizziness	2 patients Disc. AE	200 mg 1 times / day steady, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9758292/	unhealthy, adult n = 881 Health Status: unhealthy Condition: chronic bronchitis or pneumonia Age Group: adult Sex: M+F Population Size: 881 Sources: https://pubmed.ncbi.nlm.nih.gov/9758292/
CNS disorder (NOS)	4 patients Disc. AE	200 mg 1 times / day steady, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9758292/	unhealthy, adult n = 881 Health Status: unhealthy Condition: chronic bronchitis or pneumonia Age Group: adult Sex: M+F Population Size: 881 Sources: https://pubmed.ncbi.nlm.nih.gov/9758292/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 1461	UGT 192 sulfotransferases 38

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 1650	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/23401306/	yes

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
UGT 192	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a_clinpharmr.pdf#page=4 Page: 4.0	yes
sulfotransferases 38	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020760a_clinpharmr.pdf#page=4 Page: 4.0	yes

Sourcing

Vendor/Aggregator	ID	URL
AHH Chemical co.,ltd	MB-18104	http://www.ahhchemical.com/product/MB-18104.html
AK Scientific, Inc. (AKSCI)	X2115	http://www.aksci.com/item_detail.php?cat=X2115
Alfa Chemistry	146961-76-4	https://www.alfa-chemistry.com/alatrofloxacin-cas-146961-76-4-item-290329.htm
BOC Sciences	146961-76-4	https://www.bocsci.com/l-alaninamide-l-alanyl-n-1a-5a-6a-3-6-carboxy-8-2-4-difluorophenyl-3-fluoro-5-8-dihydro-5-oxo-1-8-naphthyridin-2-yl-3-azabicyclo-3-1-0-hex-6-yl-cas-146961-76-4-item-166826.html
BioSynth	J-008289	https://www.biosynth.com/en/products/all-products/products/J-008289.html
ChEBI	CHEBI:9763	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:9763
ChemMol	99045884	http://www.chemmol.com/chemmol/99045884.html
Lab Network	LN01284338	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01284338
MolPort	MolPort-018-615-902	https://www.molport.com/shop/molecule-link/MolPort-018-615-902
MuseChem	M093915	https://www.musechem.com/product/M093915.html
Smolecule	S517830	http://www.smolecule.com/products/s517830
THE BioTek	bt-259048	https://www.thebiotek.com/product/inhibitors/bt-259048
ZINC	ZINC000100030989	http://zinc15.docking.org/substances/ZINC000100030989
eNovation Chemicals	D674817	https://www.enovationchem.com/ProductDetails.asp?ProductID=D674817

PubMed

Title	Date	PubMed
The 2-pyridone antibacterial agents: 8-position modifications.	1999 Jul	10438895
Anti-toxoplasma activities of 24 quinolones and fluoroquinolones in vitro: prediction of activity by molecular topology and virtual computational techniques.	2000 Oct	10991859
In vitro susceptibility and eradication of Chlamydia pneumoniae cardiovascular strains from coronary artery endothelium and smooth muscle cells.	2001	11713894
Latest industry information on the safety profile of levofloxacin in Japan.	2001	11549788
Comparison of side effects of levofloxacin versus other fluoroquinolones.	2001	11549784
Sub-inhibitory concentrations of vancomycin prevent quinolone-resistance in a penicillin-resistant isolate of Streptococcus pneumoniae.	2001	11454238
Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States.	2001 Apr	11404068
In vitro activity of gemifloxacin (SB-265805) compared to eleven other antimicrobial agents against streptococcal isolates, excluding Streptococcus pneumoniae.	2001 Apr	11399019
Trovafloxacin hepatotoxicity.	2001 Apr	11330435
Peripheral neuropathy associated with fluoroquinolones.	2001 Dec	11793615
Differences between two new quinolones (gemifloxacin and trovafloxacin) and ciprofloxacin in their concentration-dependent killing of Streptococcus pneumoniae.	2001 Dec	11786655
pH-metric solubility. 3. Dissolution titration template method for solubility determination.	2001 Dec	11684402
Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition.	2001 Feb	11210403
Trovafloxacin-associated leukopenia.	2001 Jan	11197584
Multifocal Staphylococcus aureus infection originating from the sacroiliac joint in a patient with rheumatoid arthritis.	2001 Jan	11196533
Pfizer accused of testing new drug without ethical approval.	2001 Jan 27	11159610
Comparative in vitro bacteriostatic and bactericidal activity of trovafloxacin, levofloxacin and moxifloxacin against clinical and environmental isolates of Legionella spp.	2001 Jul	11463526
Comparative killing kinetics of the novel des-fluoro(6) quinolone BMS-284756, fluoroquinolones, vancomycin and beta-lactams.	2001 Jul	11463525
Experimental intravitreal application of trovafloxacin in rabbits.	2001 Jul-Aug	11464076
Resistance to antibiotics and biocides among non-fermenting Gram-negative bacteria.	2001 Jun	11442564
Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents.	2001 Jun	11397615
Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae.	2001 Jun	11389122
Comparative in-vitro activity of trovafloxacin and other related drugs against isolates of streptococcus oralis.	2001 Mar	11307110
Antimicrobial safety and tolerability: differences and dilemmas.	2001 Mar 15	11249832
Comparative in vitro activity of the new quinolone gemifloxacin (SB-265805) with other fluoroquinolones against respiratory tract pathogens.	2001 May	11328784
Activity of BMS284756 (T-3811) tested against anaerobic bacteria, Campylobacter jejuni, Helicobacter pylori and Legionella spp.	2001 May-Jun	11448563
In vitro activity of ABT-773 versus macrolides and quinolones against resistant respiratory tract pathogens.	2001 May-Jun	11448561
A comparative study of the fluoroquinolone antibacterial agents on the action potential duration in guinea pig ventricular myocardia.	2001 Nov	11885973
Fluoroquinolone susceptibilities of efflux-mediated multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Burkholderia cepacia.	2001 Oct	11581236
Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.	2001 Sep	11533001
Drug company sued over research trial in Nigeria.	2001 Sep 8	11564494
In vitro susceptibility of Stenotrophomonas maltophilia to various antimicrobial combinations.	2001 Sep-Oct	11687317
In vitro activity of novel fluoroquinolones against Streptococcus pneumoniae isolated from children with acute otitis media.	2001 Sep-Oct	11561138
Molecular epidemiology and mutations at gyrA and parC genes of ciprofloxacin-resistant Escherichia coli isolates from a Taiwan medical center.	2001 Spring	11310803
Moxifloxacin sensitivity of respiratory pathogens in the United Kingdom.	2002 Feb	11892894
In vitro activity of clinafloxacin in comparison with other quinolones against Stenotrophomonas maltophilia clinical isolates in the presence and absence of reserpine.	2002 Feb	11858908
Susceptibility of human isolates of Salmonella typhimurium DT 104 to antimicrobial agents used in human and veterinary medicine.	2002 Jan	11821166
Pharmacological evaluation of garenoxacin, a novel des-F(6)-quinolone antimicrobial agent: effects on the central nervous system.	2003 Feb	12696183
Evaluation of high-dose daptomycin for therapy of experimental Staphylococcus aureus foreign body infection.	2006 Apr 11	16608512
Secret report surfaces showing that Pfizer was at fault in Nigerian drug tests.	2006 May 27	16735322
Pfizer lawsuit spotlights ethics of developing world clinical trials.	2007 Jul	17618250
Drug company trials come under increasing scrutiny.	2008 Jan 19	18217230
Antimicrobial prophylaxis in colorectal surgery: focus on ertapenem.	2009	19898647
Globalized clinical trials and informed consent.	2009 May 14	19439740

Patents

Sample Use Guides

In Vivo Use Guide

Nosocomial Pneumonia - 300 mg I.V. followed by 200 mg oral, 10–14 days Community Acquired Pneumonia - 200 mg oral or 200 mg I.V. followed by 200 mg oral, 7–14 days Gynecologic and Pelvic Infections - 300 mg I.V. followed by 200 mg oral, 7–14 days

Route of Administration: Other

In Vitro Use Guide

Trovafloxacin inhibited Escherichia coli growth with MIC50 = 0.125mg/L

Substance Class	Chemical Created by `admin` on `Sat Dec 16 04:59:39 GMT 2023` Edited by `admin` on `Sat Dec 16 04:59:39 GMT 2023`
Record UNII	546454T03O
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TROVAFLOXACIN HYDROCHLORIDE

Common Name

English

1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID, 7-(6-AMINO-3-AZABICYCLO(3.1.0)HEX-3-YL)-1-(2,4-DIFLUOROPHENYL)-6-FLUORO-1,4-DIHYDRO-4-OXO-, MONOHYDROCHLORIDE, (1.ALPHA.,5.ALPHA.,6.ALPHA.)-

Common Name

English

TROVAFLOXACIN HYDROCHLORIDE [MI]

Common Name

English

Code System Code Type Description

FDA UNII

546454T03O